ABIO:NSD-ARCA biopharma, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 6.43

Change

-0.31 (-4.60)%

Market Cap

USD 0.01B

Volume

0.42M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Company Website : http://arcabio.com

Address : 11080 CirclePoint Road, Westminster, CO, United States, 80020

Employees : 13

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 3.15

52 Week High : 15.00

52 Week Low : 2.21

Shorted Shares : 15,478

200 Day Moving Average : 5.06

Shorted Shares Previous Month : 8,479

50 Day Moving Average : 7.23

Shares Held By Insiders : 5.69%

Short Percentage : 1.00%

Shares Held by Institutions : 13.28%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+0.21 (+0.07%)

 USD75.50B 48.39 36.24
REGN Regeneron Pharmaceuticals, Inc

+4.80 (+0.77%)

 USD62.07B 30.02 20.75
SGEN Seattle Genetics, Inc

+1.42 (+0.84%)

 USD29.51B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+1.27 (+1.13%)

 USD25.08B 10.60 9.11
INCY Incyte Corporation

+1.32 (+1.24%)

 USD22.68B 47.64 35.20
MRNA Moderna, Inc

+0.58 (+0.99%)

 USD21.96B N/A N/A
BMRN BioMarin Pharmaceutical Inc

+0.93 (+0.73%)

 USD21.81B 193.21 115.90
GMAB Genmab A/S

+0.82 (+2.45%)

 USD21.51B 59.03 6.26
ALNY Alnylam Pharmaceuticals, Inc

+2.56 (+1.71%)

 USD17.42B N/A N/A
BGNE BeiGene, Ltd

+0.86 (+0.44%)

 USD15.19B N/A N/A

ETFs Containing ABIO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.61% 59% F 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.61% 59% F 74% C
Trailing 12 Months  
Capital Gain -7.35% 43% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.35% 43% F 50% F
Trailing 5 Years  
Capital Gain -95.27% 16% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -95.27% 15% F 5% F
Average Annual (5 Year Horizon)  
Capital Gain -45.68% 4% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.68% 4% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 23.35% 91% A- 67% D+
Risk Adjusted Return -195.65% 2% F 1% F
Market Capitalization 0.01B 5% F 7% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.76 35% F 48% F
Price/Book Ratio 2.08 81% B- 52% F
Price / Cash Flow Ratio -2.60 31% F 68% D+
EV/EBITDA 0.07 79% C+ 97% A+
Management Effectiveness  
Return on Equity -75.43% 46% F 17% F
Return on Invested Capital -82.79% 33% F 11% F
Return on Assets -41.80% 27% F 8% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent 0.80% 87% B+ 79% C+
Beta 3.15 3% F 3% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.